These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway. Liu X; Zhang F; Fan Y; Qiu C; Wang K Int Immunopharmacol; 2024 Dec; 142(Pt A):113107. PubMed ID: 39276458 [TBL] [Abstract][Full Text] [Related]
3. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941 [TBL] [Abstract][Full Text] [Related]
4. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma. Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968 [TBL] [Abstract][Full Text] [Related]
5. Dihydroartemisinin Induces Ferroptosis in HCC by Promoting the Formation of PEBP1/15-LO. Su Y; Zhao D; Jin C; Li Z; Sun S; Xia S; Zhang Y; Zhang Z; Zhang F; Xu X; Shao J; Zhang B; Zheng S Oxid Med Cell Longev; 2021; 2021():3456725. PubMed ID: 34925691 [TBL] [Abstract][Full Text] [Related]
6. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470 [TBL] [Abstract][Full Text] [Related]
7. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. Huang CY; Chen LJ; Chen G; Chao TI; Wang CY Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407 [TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells. Chen Y; Mi Y; Zhang X; Ma Q; Song Y; Zhang L; Wang D; Xing J; Hou B; Li H; Jin H; Du W; Zou Z J Exp Clin Cancer Res; 2019 Sep; 38(1):402. PubMed ID: 31519193 [TBL] [Abstract][Full Text] [Related]
9. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718 [TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism. Cui Z; Wang H; Li S; Qin T; Shi H; Ma J; Li L; Yu G; Jiang T; Li C J Pharmacol Sci; 2022 Jan; 148(1):73-85. PubMed ID: 34924133 [TBL] [Abstract][Full Text] [Related]
11. Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma. Zhuang M; Zhang X; Li LU; Wen L; Qin J Oncol Res; 2024; 32(8):1347-1357. PubMed ID: 39055886 [TBL] [Abstract][Full Text] [Related]
12. Identification of SLC7A11-AS1/SLC7A11 pair as a ferroptosis-related therapeutic target for hepatocellular carcinoma. Yuan X; Wang Y; Jiao S; Gao H; Zhang M; Wang X; Zhou X; Wu C; Bao J J Cell Mol Med; 2024 Jul; 28(13):e18496. PubMed ID: 38984939 [TBL] [Abstract][Full Text] [Related]
13. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265 [TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin enhances the radiosensitivity of breast cancer by targeting ferroptosis signaling pathway through hsa_circ_0001610. Zhang Y; Cao S; Zeng F; Pan D; Cai L; Zhou Y; Wang H; Qin G; Zhang C; Chen W Eur J Pharmacol; 2024 Nov; 983():176943. PubMed ID: 39182549 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma. Liu Y; Shao K; Yang W; Shen Q; Lu M; Shao Z; Chu S; Wang Y; Wang X; Chen X; Bai J; Wu X Cell Death Dis; 2024 Jun; 15(6):395. PubMed ID: 38839744 [TBL] [Abstract][Full Text] [Related]
16. APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy. Du Y; Zhou Y; Yan X; Pan F; He L; Guo Z; Hu Z Cell Death Differ; 2024 Apr; 31(4):431-446. PubMed ID: 38418695 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107 [TBL] [Abstract][Full Text] [Related]
18. ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner. Chen D; Fan Z; Rauh M; Buchfelder M; Eyupoglu IY; Savaskan N Oncogene; 2017 Oct; 36(40):5593-5608. PubMed ID: 28553953 [TBL] [Abstract][Full Text] [Related]
19. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3. Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750 [TBL] [Abstract][Full Text] [Related]
20. RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA. Wang Q; Guo Y; Wang W; Liu B; Yang G; Xu Z; Li J; Liu Z Exp Cell Res; 2021 Feb; 399(1):112453. PubMed ID: 33358859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]